During the trials, adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of vaccines from other manufacturers to establish the safety and immunogenicity of mixed booster regimens.
The US National Institutes of Health (NIH) has begun the first phase of a study on the effects of an additional, third dose of a COVID-19 vaccine from another manufacturer. This was reported by the press service of the scientific center.
According to her, during the trials, adult volunteers who have been fully vaccinated against COVID-19 will receive booster doses of vaccines from other manufacturers to establish the safety and immunogenicity of mixed booster regimens.
“Although the vaccines currently approved by the US Food and Drug Administration (FDA) provide reliable protection against COVID-19, we must be prepared for the need to reintroduce vaccines to prevent the weakening of immunity and provide protection against the developing virus,” the NIH press service quotes Anthony Fauci, director of the National Institute of Allergic and Infectious Diseases of the United States. According to him, the relevant study will prepare the ground for deciding on the revaccination of the mixed type if necessary.
Preliminary test results are expected in late summer 2021. The volunteers who received the booster dose during this study will be monitored for a year. According to WHO data as of June 1, the United States ranks first among countries in the world in the number of cases of coronavirus infection – 32,929,178 people, as well as in the number of deaths – 588,596 people.
